| A Comparative Study of the Transdermal Penetration of a Series of Nonsteroidal Antiinflammatory Drugs JA Cordero, L Alarcon, E Escribano, R Obach, J Domenech Journal of Pharmaceutical Sciences 86 (4), P503-508, 1997 | 256 | 1997 |
| In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs JA Cordero, M Camacho, R Obach, J Domenech, L Vila European Journal of Pharmaceutics and Biopharmaceutics 51 (2), 135-142, 2001 | 103 | 2001 |
| Anti-vascular endothelial growth factor for proliferative diabetic retinopathy MJ Martínez-Zapata, AJ Martí-Carvajal, I Solà, JI Pijoán, JA Buil-Calvo, ... Cochrane Database of Systematic Reviews 2023 (CD008721), 2023 | 101 | 2023 |
| Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy MJ Martinez‐Zapata, AJ Martí‐Carvajal, I Solà, JI Pijoán, JA Buil‐Calvo, ... Cochrane Database of Systematic Reviews 11, 1465-1858, 2014 | 101* | 2014 |
| Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers RM Antonijoan, MJ Barbanoj, C JA, P C, O R, V J, Chérif-Cheikh R, T M-L, ... Journal of Pharmacy and Pharmacology 56 (4), 471–476, 2004 | 61 | 2004 |
| Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency Barbanoj, A M, M R, G AM, S J, J Vallès, C Peraire, JA Cordero, A Muñoz, ... Clinical Pharmacology and Therapeutics, 485–491, 1999 | 26 | 1999 |
| Autogel®: A new lanreotide prolonged release formulation R Cherif-Cheikh, F Bismuth, ML Torres, R Alloza, MT Bosch, M Montes, ... Proceedings of the Controlled Release Society, 798-799, 1998 | 16 | 1998 |
| Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof R Cherif-Cheikh, ZX Dong, MDT Maestre, JA Cordero-Rigol, F Lacombe US Patent App. 12/226,257, 2010 | 15 | 2010 |
| GLP-1 pharmaceutical compositions ZX Dong, R Cherif-Cheikh, RA Miravete, JAC Rigol, F Lacombe, ... US Patent 8,236,759, 2012 | 10 | 2012 |
| Glp-1 pharmaceutical compositions ZX Dong, R Cherif-Cheikh, JA Cordero-Rigol, RA Miravete, F Lacombe, ... US Patent App. 12/448,631, 2010 | 9 | 2010 |
| Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach X Bonfill, I Arevalo-Rodriguez, L Martínez García, MJ Quintana, ... Cancer Management and Research 2018, 2357—2367, 2018 | 8 | 2018 |
| AA comparative study of the transdermal penetration of a series of nonsteroidal an tiinflamatory dmgs J CORDERO JPHarm Sci 86, 503-510, 1997 | 7 | 1997 |
| Population-based estimate of the use of intermittent androgen deprivation therapy in prostate cancer patients in Catalonia, Spain JA Cordero, G Sancho, X Bonfill Pharmacoepidemiology & Drug Safety 28 (6), 796-803, 2019 | 5 | 2019 |
| Pharmacokinetic profile of a SRF formulation of BIM51077, a novel GLP-1 analog, in the beagle dog J Ramis, A Menargues, JA Allue, C Peraire, JA Cordero, R Cherifcheikh Diabetes 55, A130-A130, 2006 | 3 | 2006 |
| GLP-1 pharmaceutical compositions Z Dong, R Miravete, R Cherif-Cheikh, JA Rigol, F Lacombe, M Maestre US Patent App. 11/647,746, 2007 | 1 | 2007 |
| Pharmacokinetics and oral bioavailability of BN80915, a novel topoisomerase I inhibitor, after single dose administration in rats. A Menargues, C Celma, JA Cordero, D Basart, R Obach, C Peraire, ... CLINICAL CANCER RESEARCH 5, 3840S-3841S, 1999 | 1 | 1999 |
| Estudios de permeación transdérmica y actividad tópica de una serie de antiinflamatorios no esteroides JA Cordero Universitat de Barcelona, 1998 | 1 | 1998 |
| Named Entity Recognition of Pharmacokinetic parameters in the scientific literature FG Hernandez, Q Nguyen, VC Smith, JA Cordero, MR Ballester, M Duran, ... bioRxiv, 2024.02. 12.580001, 2024 | | 2024 |
| Inteligencia Artificial aplicada al diseño y desarrollo de fármacos JA Cordero, M Poch, M Duran, V Smith, MR Ballester InfoEdita, 2023 | | 2023 |
| Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain JA Cordero | | 2022 |
